CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin, Regina
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. [electronic resource] - Journal for immunotherapy of cancer 11 2018 - 116 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2051-1426
10.1186/s40425-018-0432-9 doi
Female
Humans
Leukemia, Myeloid, Acute--immunology
Male
Monocytes--metabolism
Myeloid-Derived Suppressor Cells--immunology
Sialic Acid Binding Ig-like Lectin 3--metabolism
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. [electronic resource] - Journal for immunotherapy of cancer 11 2018 - 116 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2051-1426
10.1186/s40425-018-0432-9 doi
Female
Humans
Leukemia, Myeloid, Acute--immunology
Male
Monocytes--metabolism
Myeloid-Derived Suppressor Cells--immunology
Sialic Acid Binding Ig-like Lectin 3--metabolism